[1
]
Jacquie H. Chirgwin and John F. Forbes, University of Newcastle; John F. Forbes, Calvary
Mater Newcastle, Newcastle; Alan S. Coates, University of Sydney School of Public
Health, Sydney, New South Wales; Jacquie H. Chirgwin, Box Hill Hospital; Jacquie H.
Chirgwin, Maroondah Hospital; Jacquie H. Chirgwin, Monash University, Melbourne, Victoria,
Australia; Anita Giobbie-Hurder, Karen N. Price, and Richard D. Gelber, International
Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Karen
N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation;
Richard D. Gelber, Harvard Medical School, Boston, MA; Bent Ejlertsen, Rigshospitalet,
Copenhagen, Denmark; Marc Debled, Institut Bergonié, Bordeaux, France; Aron Goldhirsch
and Marco Colleoni, European Institute of Oncology, Milan, Italy; Ian Smith, The Royal
Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Manuela
Rabaglio, Inselspital, Bern; Beat Thürlimann, Kantonsspital, St. Gallen, Switzerland;
Patrick Neven, University of Leuven; Patrick Neven, University Hospitals Leuven, Leuven,
Belgium; István Láng, National Institute of Oncology, Budapest, Hungary. chirgwin@tpg.com.au.
[2
]
Jacquie H. Chirgwin and John F. Forbes, University of Newcastle; John F. Forbes, Calvary
Mater Newcastle, Newcastle; Alan S. Coates, University of Sydney School of Public
Health, Sydney, New South Wales; Jacquie H. Chirgwin, Box Hill Hospital; Jacquie H.
Chirgwin, Maroondah Hospital; Jacquie H. Chirgwin, Monash University, Melbourne, Victoria,
Australia; Anita Giobbie-Hurder, Karen N. Price, and Richard D. Gelber, International
Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Karen
N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation;
Richard D. Gelber, Harvard Medical School, Boston, MA; Bent Ejlertsen, Rigshospitalet,
Copenhagen, Denmark; Marc Debled, Institut Bergonié, Bordeaux, France; Aron Goldhirsch
and Marco Colleoni, European Institute of Oncology, Milan, Italy; Ian Smith, The Royal
Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Manuela
Rabaglio, Inselspital, Bern; Beat Thürlimann, Kantonsspital, St. Gallen, Switzerland;
Patrick Neven, University of Leuven; Patrick Neven, University Hospitals Leuven, Leuven,
Belgium; István Láng, National Institute of Oncology, Budapest, Hungary.
